Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bay Shore, NY
NPI
1710901558
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
53 Brentwood Rd, Suite E
Bay Shore, NY, 11706
Phone (631) 666-6275
Medicare paid, 2024
$197K
7,516 services
Medicare patients, 2024
658
Average age 75
Drug cost, 2024
$2.1M
4,615 prescriptions
Company payments, 2025
$273
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Leonard V Gioia was code 36415 (venipuncture blood collection), 1,326 times for 630 patients. In total Leonard V Gioia billed 7,516 services in 14 codes, and Medicare paid $197K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-07-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 1,326 | 630 | $8.64 | $11K |
| 99214 Office E&M - Established | Office | 1,160 | 564 | $99.71 | $116K |
| 82948 Clinical Chemistry | Office | 997 | 351 | $4.94 | $4,925 |
| 83036 Blood Count | Office | 960 | 351 | $9.52 | $9,139 |
| 84480 Clinical Chemistry | Office | 696 | 562 | $13.90 | $9,674 |
| 84443 Clinical Chemistry | Office | 696 | 565 | $16.44 | $11K |
| 84436 Clinical Chemistry | Office | 694 | 560 | $6.73 | $4,671 |
| 84479 Clinical Chemistry | Office | 692 | 559 | $6.34 | $4,387 |
| 99204 Office E&M - New | Office | 127 | 127 | $133.67 | $17K |
| 99213 Office E&M - Established | Office | 111 | 91 | $71.68 | $7,956 |
| 81002 Clinical Chemistry | Office | 30 | 30 | $3.41 | $102 |
By year: 2022 $182K for 7,078 services; 2023 $177K for 6,358 services; 2024 $197K for 7,516 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,326 | 630 | $8.64 | $11K |
| 82948 Clinical Chemistry | 997 | 351 | $4.94 | $4,925 |
| 83036 Blood Count | 960 | 351 | $9.52 | $9,139 |
| 84480 Clinical Chemistry | 696 | 562 | $13.90 | $9,674 |
| 84443 Clinical Chemistry | 696 | 565 | $16.44 | $11K |
| 84436 Clinical Chemistry | 694 | 560 | $6.73 | $4,671 |
| 84479 Clinical Chemistry | 692 | 559 | $6.34 | $4,387 |
| 81002 Clinical Chemistry | 30 | 30 | $3.41 | $102 |
Medicare prescription drug claims, 2024
In 2024, the drug Leonard V Gioia prescribed most often to Medicare patients was Levothyroxine Sodium, with 738 prescriptions and refills. In total Leonard V Gioia wrote 4,615 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 738 | 2,191 | 222 | $14K |
| Glimepiride Generic | 509 | 1,422 | 149 | $5,179 |
| Metformin Hcl Generic | 381 | 1,073 | 119 | $2,870 |
| Metformin Hcl Er Metformin Hcl | 268 | 752 | 88 | $2,151 |
| Ozempic Semaglutide | 231 | 416 | 51 | $383K |
| Jardiance Empagliflozin | 229 | 615 | 60 | $338K |
| Synthroid Levothyroxine Sodium | 227 | 657 | 58 | $11K |
| Mounjaro Tirzepatide | 196 | 281 | 45 | $286K |
| Trulicity Dulaglutide | 190 | 378 | 50 | $366K |
| Pioglitazone Hcl Generic | 184 | 551 | 57 | $2,599 |
| Januvia Sitagliptin Phosphate | 153 | 394 | 42 | $205K |
| Atorvastatin Calcium Generic | 128 | 347 | 40 | $822 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 119 | 240 | 33 | $30K |
| Glipizide Er Glipizide | 115 | 347 | 34 | $2,140 |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 93 | 272 | 34 | $9,150 |
Brand drugs: 1,972 claims; generic drugs: 2,413 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Leonard V Gioia $273 ($273 in general payments such as food, travel and fees) from 5 companies. The largest payer was Abbvie Inc. with $141.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.